Brought to you by 
Qiagen acquires stake in Ipsogen
24 Jan 2012
Executive Summary
Sample and assay technologies developer Qiagen NV has offered €12.90 ($18.63, a 71% premium) per share to acquire 47% of public molecular diagnostics firm Ipsogen SA. Immediately following the signing of a definitive agreement and the commencement of the initial purchase, Qiagen will begin the process of acquiring the remaining 53% of Ipsogen. The total value of the deal is €65mm based on 5mm shares outstanding.
Deal Industry
- Biotechnology
- In Vitro Diagnostics
-
Research, Analytical Equipment & Supplies
- PCR & Amplification Tools
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
Deal Status
- Final
Deal Type
-
Acquisition
- Intra-Biotech Deal
- Partial Acquisition
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com